This Article Full Text Full Text (PDF) All Versions of this Article: 35/2/528    most recent 01.STR.0000110221.54366.49v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ringleb, P. A. Search for Related Content PubMed PubMed Citation Articles by Ringleb, P. A. Related Collections Primary and Secondary Stroke Prevention Risk Factors for Stroke Antiplatelets

(Stroke. 2004;35:528.)
© 2004 American Heart Association, Inc.

Original Contributions

Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events

Peter A. Ringleb, MD; Deepak L. Bhatt, MD; Alan T. Hirsch, MD; Eric J. Topol, MD Werner Hacke, MD, PhD for the CAPRIE Investigators

From the Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany (P.A.R., W.H.); Vascular Medicine Program, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Minneapolis (A.T.H.); and Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio (D.L.B., E.J.T.).

Correspondence to Peter A. Ringleb, MD, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, D-69120 Heidelberg, Germany. E-mail Werner_Hacke{at}med.uni-heidelberg.de

Background and Purpose— The goal of this study was to examine the influence of preexisting symptomatic atherosclerotic disease on subsequent ischemic event rates and compare the efficacy of clopidogrel versus aspirin (acetylsalicylic acid, ASA) in patients with such disease.

Methods— Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial. Two composite end points were used: (1) IS, MI, or vascular death and (2) IS, MI, or rehospitalization for ischemia.

Results— In the CAPRIE population, prior IS and MI each were statistically significant predictors of subsequent ischemic events. Compared with the overall population, patients with preexisting symptomatic atherosclerotic disease had elevated event rates for the end point of IS, MI, or vascular death; 3-year rates were 20.4% with clopidogrel and 23.8% with ASA (absolute risk reduction, 3.4%; 95% CI, -0.2 to 7.0; number needed to treat, 29; relative risk reduction, 14.9%; P=0.045). Similar results were obtained for the end point of IS, MI, or rehospitalization for ischemia; 3-year event rates were 32.7% with clopidogrel and 36.6% with ASA (absolute risk reduction, 3.9%; 95% CI, -0.4 to 8.1; number needed to treat, 26; relative risk reduction, 12.0%; P=0.039).

Conclusions— CAPRIE patients with a history of prior symptomatic atherosclerotic disease had a high rate of subsequent ischemic events. The absolute benefit of clopidogrel over ASA seemed to be amplified in such high-risk patients.

Key Words: aspirin • clopidogrel • patients • randomized controlled trials

This article has been cited by other articles:

				P. P. Cacoub, D. L. Bhatt, P.G. Steg, E. J. Topol, M. A. Creager, and for the CHARISMA Investigators Patients with peripheral arterial disease in the CHARISMA trial Eur. Heart J., January 9, 2009; (2009) ehn534v1. [Abstract] [Full Text] [PDF]

				J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell Antiplatelet Agents in the Perioperative Period Arch Surg, January 1, 2009; 144(1): 69 - 76. [Abstract] [Full Text] [PDF]

				P. Talelli and R. J. Greenwood Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease, October 1, 2008; 2(5): 387 - 405. [Abstract] [PDF]

				M. R. BAKHRU and D. L. BHATT INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin? Cleveland Clinic Journal of Medicine, April 1, 2008; 75(4): 289 - 295. [Abstract] [Full Text] [PDF]

				N. A. Nickman, J. Biskupiak, F. Creekmore, H. Shah, and D. I . Brixner Antiplatelet medication management in patients hospitalized with ischemic stroke Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2250 - 2256. [Abstract] [Full Text] [PDF]

				D. L. Bhatt, M. D. Flather, W. Hacke, P. B. Berger, H. R. Black, W. E. Boden, P. Cacoub, E. A. Cohen, M. A. Creager, J. D. Easton, et al. Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1982 - 1988. [Abstract] [Full Text] [PDF]

				T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF]

				G. E. Kikano and M. T. Brown Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician Mayo Clin. Proc., May 1, 2007; 82(5): 583 - 593. [Abstract] [Full Text] [PDF]

				E. I. de Oliveira and D. L. Bhatt Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G10 - G14. [Abstract] [Full Text] [PDF]

				H.-C. Diener Update on clopidogrel and dual anti-platelet therapy: neurology Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G15 - G19. [Abstract] [Full Text] [PDF]

				M. S. Randall, F. M. McKevitt, G. S. Venables, T. J. Cleveland, and P. A. Gaines Response to Letter by Kramer et al Stroke, June 1, 2006; 37(6): 1360 - 1360. [Full Text] [PDF]

				R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation, March 14, 2006; 113(10): e409 - e449. [Abstract] [Full Text] [PDF]

				R. P Raghavan, D. W Laight, K. M Shaw, and M. H Cummings Review: Aspirin and diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 74 - 82. [Abstract] [PDF]

				R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, February 1, 2006; 37(2): 577 - 617. [Abstract] [Full Text] [PDF]

				I. A. Ferreira, A. I.M. Mocking, M. A.H. Feijge, G. Gorter, T. W. van Haeften, J. W.M. Heemskerk, and J.-W. N. Akkerman Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 417 - 422. [Abstract] [Full Text] [PDF]

				H. S. Kirshner, J. Biller, and A. S. Callahan III Long-Term Therapy to Prevent Stroke J Am Board Fam Med, November 1, 2005; 18(6): 528 - 540. [Abstract] [Full Text] [PDF]

				I. E. Hoefer, S. Grundmann, S. Schirmer, N. van Royen, B. Meder, C. Bode, J. J. Piek, and I. R. Buschmann Aspirin, But Not Clopidogrel, Reduces Collateral Conductance in a Rabbit Model of Femoral Artery Occlusion J. Am. Coll. Cardiol., September 20, 2005; 46(6): 994 - 1001. [Abstract] [Full Text] [PDF]

				R. Donnelly Antiplatelet therapy and prevention of ischaemic events: CAPRIE The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 203 - 206. [PDF]

				D. L. Bhatt and J. Hirsh The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin--Reply Arch Intern Med, June 13, 2005; 165(11): 1310 - 1311. [Full Text] [PDF]

				J. Hirsh and D. L. Bhatt Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations: Lessons From the CAPRIE and CURE Studies Arch Intern Med, October 25, 2004; 164(19): 2106 - 2110. [Abstract] [Full Text] [PDF]

				S. C. Lewis and C. P. Warlow There Is No Evidence That the Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events Stroke, October 1, 2004; 35(10): 2241 - 2241. [Full Text] [PDF]

				Other articles noted Evid. Based Med., May 1, 2004; 9(3): 95 - 96. [Full Text] [PDF]